"Specific Baculovirus Major Envelope Glycoprotein Gp64 Binding Proteins" in Patent Application Approval Process (USPTO 20240352076).
| Předmět: | |
|---|---|
| Zdroj: | Vaccine Weekly; 11/13/2024, p422-422, 1p |
| Abstrakt: | A patent application by Navigo Proteins GmbH in Germany aims to simplify and improve the purification process of vaccines produced using a baculovirus-insect cell expression system. The invention involves novel binding proteins for the major contaminant glycoprotein 64 (gp64) found in vaccine preparations, allowing for more efficient purification through affinity chromatography. The patent application outlines specific amino acid sequences and methods for capturing and isolating gp64, enhancing the quality of vaccine production. [Extracted from the article] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|